指南与共识泌尿生殖技术与安全PETCT

SPARC:标准化前列腺特异性膜抗原正电子发射断层显像/计算机断层显像分析与报告共识:一项德尔菲分析

SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis.
指南 / 共识 · Eur Urol · 2025-09-13

SPARC项目由多学科国际专家组采用两轮改良德尔菲调查和RAND适宜性方法,对91条关于PSMA PET/CT标准化报告、检测、原发分期、生化复发和治疗反应的陈述进行共识评估,共识度升至93%。专家组采纳分子影像PSMA表达水平与确定性、PROMISE的miTNM、PRIMARY评分、PSMA体积、平均标准化摄取值和最大标准化摄取值(SUVmax)等报告框架,但对PSMA PET/CT与常规影像风险分组的相关性、基于PSMA PET/CT的临床管理计划改善结局存在不确定性,且数据不足以标准化治疗反应或进展的定义。

要点

  • 报告应采用分子影像PSMA表达水平与确定性、PROMISE的miTNM、PRIMARY评分、PSMA体积、平均标准化摄取值和SUVmax等框架。
  • SUVmax应区域化报告,而非报告单个部位。
  • 数据不足以标准化PSMA PET/CT的治疗反应或进展定义。

核心结论

  • SPARC提供标准化PSMA PET/CT分析与报告共识,作为未来PSMA PET/CT报告的参考;将常见PSMA PET报告标准整合到统一框架下,有助于影像专家与治疗临床医生之间解释影像发现以促进临床实施。

研究设计与样本

  • 横断面迭代过程,30名专家组成员,代表不同专业和地区;由方法学专家领导设计、数据收集和分析;五组国际多学科前列腺癌专家组进行文献回顾并制定关于标准化报告、检测、原发分期、生化复发和治疗反应的陈述,共91条陈述进行两轮改良德尔菲调查,采用RAND适宜性方法分析。

诊断标准与关键数值

  • 两轮之间共识度增至93%。
  • 专家组采纳分子影像PSMA用于表达水平和确定性报告。
  • 专家组采纳PROMISE的miTNM用于PSMA PET/CT报告。
  • 专家组采纳PRIMARY评分用于前列腺内分期。
  • 专家组采纳PSMA体积、平均标准化摄取值和最大标准化摄取值(SUVmax)报告。

临床应用与阅片要点

  • 报告PSMA PET/CT时应采用分子影像PSMA表达水平与确定性、PROMISE的miTNM、PRIMARY评分、PSMA体积、平均标准化摄取值和SUVmax等框架。
  • SUVmax应区域化报告,而非报告单个部位。
  • 对新诊断转移性前列腺癌,PSMA PET/CT与常规影像风险分组的相关性存在不确定性。
  • 专家组未就基于PSMA PET/CT的临床管理计划改善结局达成一致。
  • 数据不足以标准化PSMA PET/CT的治疗反应或进展定义。

局限性

  • 对新诊断转移性前列腺癌,PSMA PET/CT与常规影像风险分组的相关性存在不确定性。
  • 缺乏一致意见认为基于PSMA PET/CT的临床管理计划改善结局。
  • 数据不足以标准化PSMA PET/CT的治疗反应或进展定义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND OBJECTIVE: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is an evolving diagnostic tool for prostate cancer. There is a need to harmonise existing guidelines and reporting recommendations for PSMA PET/CT. The Standardised PSMA PET/CT Analysis and Reporting Consensus (SPARC) project aims to consolidate classifications and recommendations by a multidisciplinary and international group of experts under one cohesive framework, establishing a dynamic and evolving structure for PSMA PET/CT reporting.

METHODS: We employed a cross-sectional iterative process to define opinions and evaluate consensus. Thirty expert panel members, representing diverse specialities and geographic areas, were selected. A methods expert led the design, data collection, and analysis. Five groups of international multidisciplinary prostate cancer experts convened for literature review and formulation of statements on standardised reporting, detection, primary staging, biochemical recurrence, and treatment response. The groups compiled 91 statements for a two-round modified Delphi survey. The "RAND appropriateness method" was used for the analysis.

KEY FINDINGS AND LIMITATIONS: Consensus increased to 93% between two rounds. The panel endorsed and adopted the following frameworks for reporting of PSMA PET/CT: molecular imaging PSMA for expression level and certainty, miTNM by PROMISE for reporting of PSMA PET/CT, the PRIMARY score for intraprostatic staging, PSMA volume, mean standardised uptake value, and maximum standardised uptake value (SUVmax). There were uncertainty about correlating PSMA PET/CT with conventional imaging risk groups in newly diagnosed metastatic prostate cancer and a lack of agreement that clinical management plans based upon PSMA PET/CT improved outcomes. There was consensus that SUVmax should be reported regionally, rather than reporting a single site. There were insufficient data to standardise a definition of response or progression by PSMA PET/CT.

CONCLUSIONS AND CLINICAL IMPLICATIONS: SPARC provides a standardised PSMA PET/CT analysis and reporting consensus to serve as a future reference for PSMA PET/CT reporting. Integration of common PSMA PET reporting criteria under one umbrella improves the explanation of imaging findings between imaging experts and treating clinicians for clinical implementation.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Herrmann K, Walz J, MacLennan S, et al. SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis. Eur Urol. 2025. PMID: 40945999. doi:10.1016/j.eururo.2025.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。